A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
PHASE3
The primary purpose of this study was to see how tasisulam-sodium affected ...
Status
Terminated
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
PHASE1
The goal of this study is to determine the dose of LY573636-sodium (hereaft...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma
PHASE2
The primary purpose of the study is to estimate the time from the first dos...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
PHASE2
The primary objective is to estimate the time to progressive disease for pa...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tasisulam in Treating Participants With Malignant Melanoma
PHASE2
The primary purpose of this study is to determine the objective response ra...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
PHASE2
The primary objective is to determine whether LY573636-sodium (hereafter re...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Safety Study in Participants With Advanced Solid Tumors
PHASE1
The purpose of this study is to determine a safe dose of LY573636 (tasisula...
Status
Terminated
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1b Trial in Patients With Renal Cell Cancer
PHASE1
The purpose of this study is to determine a safe dose of LY573636-sodium to...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
PHASE1
The purpose of this study is to evaluate whether tasisulam acts as an induc...
Status
Terminated
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
PHASE1
The purpose of this study was to assess the effect of tasisulam as an inhib...
Status
Terminated
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.